RVP-001 for Healthy Subjects (HS)

Phase-Based Progress Estimates
Quotient Sciences, Miami, FL
Healthy Subjects (HS)
RVP-001 - Drug
18 - 65
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new drug, RVP-001, to see if it is safe and tolerated by healthy adults, and to understand how it is metabolized and eliminated by the body. RVP-001 is a treatment that is typically used to treat Healthy Subjects (HS). This particular treatment has previously been approved by the FDA for a different condition. The great thing about this treatment is that it is free.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

5 Primary · 1 Secondary · Reporting Duration: 5 days

5 days
PK Parameter Vd
PK parameter Cl
PK parameter t1/2
PK parameter tmax
Pharmacokinetic (PK) Parameter Cmax

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

RVP-001 group
1 of 2
Placebo group
1 of 2
Experimental Treatment
Non-Treatment Group

32 Total Participants · 2 Treatment Groups

Primary Treatment: RVP-001 · Has Placebo Group · Phase 1

RVP-001 group
Experimental Group · 1 Intervention: RVP-001 · Intervention Types: Drug
Placebo group
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics


Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 5 days
Closest Location: Quotient Sciences · Miami, FL
Photo of Miami 1Photo of Miami 2Photo of Miami 3
2017First Recorded Clinical Trial
45 TrialsResearching Healthy Subjects (HS)
66 CompletedClinical Trials

Who is running the clinical trial?

Quotient SciencesIndustry Sponsor
39 Previous Clinical Trials
1,128 Total Patients Enrolled
19 Trials studying Healthy Subjects (HS)
378 Patients Enrolled for Healthy Subjects (HS)
National Cancer Institute (NCI)NIH
12,937 Previous Clinical Trials
41,301,973 Total Patients Enrolled
61 Trials studying Healthy Subjects (HS)
25,368 Patients Enrolled for Healthy Subjects (HS)
Reveal Pharmaceuticals Inc.Lead Sponsor
Srinivasan Mukundan, MDStudy DirectorReveal Pharmaceuticals
Vera HoffmanPrincipal InvestigatorReveal Pharmaceuticals

Eligibility Criteria

Age 18 - 65 · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are a male or female who is at least 18 years of age.
Suitable veins for phlebotomy, cannulation, or repeated venipuncture.
You are informed of the study and are able to give informed consent.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.